BACKGROUND
cancer is a type of complex diseases, which generally involves multiple gene mutations and pathway dysregulations  <cit> .
identifying biomarkers for cancer can help to understand and diagnose diseases, which in turn helps to design drugs with effective therapy.
however, it is a challenging task to detect reliable biomarkers in cancers.
recently, the accumulation of large amount of “omics” data in public databases provides an opportunity for detecting biomarkers, among which the gene expression data are widely used.
accordingly, much effort has been made to identify causal disease genes based on these data.
for example, many computational methods have been developed to detect differentially expressed genes between normal and disease samples  <cit> , and these genes are supposed to be related to diseases and can be used as biomarkers.
unfortunately, many of the differentially expressed genes detected in one dataset are later found not to work effectively in another dataset for the same disease, especially for complex diseases  <cit> .
this phenomenon may arise due to the independency assumption among disease related genes when detecting differentially expressed genes, whereas complex diseases are generally caused by the dysregulation of functional modules that consist of a set of genes  <cit> .
due to the poor performance of biomarkers as differentially expressed genes, some approaches have been proposed to identify possible pathogenic pathways, which improves the robustness and accuracy when these pathways are used as biomarkers compared with above mentioned gene based methods  <cit> .
for example, lee et al.
<cit>  proposed to use a subset of genes belonging to one pathway as biomarkers to accurately distinguish diseases from controls.
liu et al.
<cit>  used pathways to compare different regions of alzheimer's disease brains and found dysfunctional pathways that cooperate in different brain regions.
despite the success of these methods on some datasets, the majority of them do not consider the functional dependency between pathways.
generally, different pathways have crosstalk with each other, and the deregulation of one pathway may affect the activities of many related pathways.
therefore, it is possible to detect more reliable pathway biomarkers by taking into account the functional dependency or interaction between pathways.
in this paper, we propose a novel method to identify dysregulated pathways by considering pathway interactions.
the identified dysregulated pathways can be used as candidate biomarkers to diagnose cancer.
specifically, a new approach is proposed to construct a pathway interaction network, which describes the functional dependency between pathways.
subsequently, the dysregulated pathways in cancer are identified as the best features to discriminate cancers from controls in a machine learning framework.
benchmarking our method on several distinct cancer datasets shows that our method outperforms previous state of the art methods.
furthermore, functional analysis and independent experimental evidence demonstrate that our identified dysregulated pathways are biologically reasonable, indicating the practical efficiency of the proposed method.
methods
datasets
gene expression data
the gene expression datasets were obtained from the ncbi gene expression omnibus   <cit> .
we chose four different types of cancer datasets that have balanced number of disease and control samples in each dataset.
table  <dig> lists the gene expression datasets that were used in this work, including lung cancer   <cit> , prostate tumour   <cit> , breast cancer   <cit> , and pancreatic tumour   <cit> .
for each gene expression dataset, the annotations for probes were obtained from geo and each probe was mapped to a gene, where the probes were discarded if they do not match any gene.
the expression value averaged over probes was used as the gene expression value if the gene has multiple probes.
subsequently, the expression values of all genes in each dataset were standardized as follows
zij=gij−meanstd
where gij represents the expression value of gene i in sample j, and mean and std respectively represents mean and standard deviation of the expression vector for gene i across all samples.
cellular pathways and human protein-protein interactions
the predefined biological pathways were obtained from the molecular signatures database   <cit> , which is a large collection of annotated functional gene sets.
we chose the canonical pathways in the curated gene sets that contain  <dig> pathways, including the metabolic and signaling pathways collected from biocarta , kegg  <cit> , and reactome  <cit> .
the human protein-protein interactions  were obtained from the human protein reference database   <cit> , which contains manually curated protein-protein interactions.
the ppi data set contains  <dig> protein interactions among  <dig> unique human proteins.
pathway activity and pathway interaction network
pathway activity
all the genes were mapped to pathways extracted from msigdb and only those genes that can be mapped to pathways were kept for further analysis hereinafter.
after the genes were mapped to pathways, we defined an activity score for each pathway as the summary of the expression values of all genes belonging to this pathway.
in particular, we used principal component analysis  method  <cit>  to get the summary of all gene expressions of each pathway.
the pca technique can effectively characterize the internal structure of high-dimension dataset by preserving the variance in the data while transforming the data into low-dimension space.
in brief, the activity score pkj of pathway k in sample j was defined as follows.
pkj=w1jkz1jk+w2jkz2jk⋯+wijkzijk
where zijk represents the standardized expression value of gene i from pathway k in sample j, and wijk denotes weight for zijk.
in other words, the activity of each pathway can be regarded as the linear combination of the expressions of all genes in the pathway, and each pathway can be regarded as a meta-gene.
in particular, the first principal component from pca was used as the activity score for the corresponding pathway here.
therefore, the pathways that have different activities in diseases between controls are possibly related to diseases.
pathway interaction network
a pathway interaction network  was constructed with each node representing a pathway, where one edge was laid between two pathways if they share at least one gene or there are interactions between genes from the two pathways based on ppis.
due to the condition-specificity of gene expression and pathway activity, for a given gene expression dataset, we further required that at least one of the common genes between two pathways is differentially expressed  between diseases and controls, or the two genes that code a pair of interacting proteins used to lay an edge between two pathways are highly co-expressed .
otherwise, the edge between two pathways will be removed.
therefore, a pathway interaction network was constructed for each dataset.
the number of pathways and corresponding interactions in each pin built for each dataset were shown in table  <dig>
identifying dysregulated pathways from pathway interaction network
after defining the activity score for each pathway, we formulated the identification of dysregulated pathways as a feature selection problem in a machine learning framework, where the minimum set of pathways that can best discriminate diseases from controls were considered to be more possibly dysregulated pathways.
it is reasonable and biologically interpretable to consider dysregulated pathways as discriminative features.
in detail, a single pathway that can best discriminate between diseases and controls was firstly identified as the first pathway biomarker, and the second pathway that can be combined with the first pathway to get better classification results was identified from those pathways that interact with the first pathway in pin.
this procedure was repeated to add new pathways to selected pathway biomarkers until no more pathways can be added to improve classification accuracy, and the final selected pathway biomarkers were retained as potential dysregulated pathways in diseases.
in feature selection, we used support vector machines , which is a widely used kernel based method especially useful for small number of samples with high dimensional variables.
in this work, the libsvm  <cit>  toolbox was used with radial basis functional  kernel.
the performance of the classifier was evaluated with five-fold cross validation, and auc  score was adopted as classification performance index.
in the five-fold cross validation, all samples were randomly split into five equal-size subsets without overlap, four of which were used as training set while the rest one was used to evaluate the classification performance.
to get robust results, we repeated five-fold cross-validation for  <dig> times and the average was used as the final result in each dataset.
RESULTS
identification of dysregulated pathways in cancer
to evaluate our method, we applied it to identify dysregulated pathways for the four cancer datasets listed in table  <dig>  moreover, we used these pathways to discriminate diseases from controls and compared our results with two classical differentially expressed gene detection methods, including the student’s t-test and biomarker identifier  method  <cit> .
in the bmi method, the differentially expressed genes were ranked by logistic regression analysis , and this method was shown to outperform other methods.
the genes selected by student’s t-test and bmi were respectively denoted as gene biomarkers and bmi biomarkers hereinafter.
for comparison with student’s t-test and bmi, we picked the same number of top ranked genes by these two methods as that of our selected pathways.
figure  <dig> shows the results obtained by gene biomarkers and bmi biomarkers compared with our method .
the dysregulated pathways identified by our method in four cancer datasets were respectively listed in tables  <dig>  we can clearly see from the results that our method outperforms the other two methods on all four different cancer datasets, indicating the effectiveness and efficiency of our proposed method.
for example, for lung cancer dataset, our method performed very well with an auc score of  <dig>  compared against gene biomarker with an auc score of  <dig>  and bmi biomarker with an auc score of  <dig> .
except for the auc score, we also compared the four methods with respect to accuracy, sensitivity and specificity .
the promising results obtained by the proposed method also demonstrate that our identified pathway biomarkers are potential dysregulated pathways in cancer.
moreover, we also compared our method with one state of the art dysregulation pathway identification method, i.e., pac  method, proposed by lee et al.
<cit> .
in the pac method, the pathway activity was defined as a combined score of a subset of genes, called the condition-responsive genes, that yields the best discriminative score.
the pathways with different discriminative power were subsequently ranked based on t-test.
we performed the pac method on above four cancer datasets.
for a fair comparison, we used the same svm toolbox and the same number of pathways identified by our method.
the results of the pac method  were also shown in figure  <dig> .
as shown in figure  <dig>  our proposed method achieved a higher auc score than the pac method on all four datasets.
these results indicate that our proposed approach helps to improve the discriminative power by taking into account the functional dependency between pathways.
furthermore, we compared the genes involved in our identified dysregulated pathways with those top ranked differentially expressed genes.
table  <dig> lists the numbers of genes involved in both our identified dysregulated pathways and those top ranked differentially expressed genes .
it is found that only a small fraction  of the genes in our identified dysregulated pathways overlaps with top ranked differentially expressed genes.
this phenomenon implies that a pathway as an entity can better diagnose complex diseases rather than individual genes even though the genes in the pathway are not differentially expressed significantly.
dysregulated pathways are robust as biomarkers
to further test our method, we applied the identified dysregulated pathways from above lung cancer dataset  to other four independent hold-out datasets of lung cancer  that are from two different affymetrix platforms, i.e., gpl <dig>  and gpl <dig> .
note that all of these test datasets list in table  <dig> are not used in above section, thereby evaluating our proposed method in an objective way.
similarly, the gene or pathway biomarkers selected from gse <dig> dataset by other methods were also applied to the four lung cancer test datasets.
the same numbers of pathways or genes as that of our selected pathways were chosen for a fair comparison.
the pathway biomarkers identified by our method achieved higher or comparable auc scores compared with other methods on all four datasets.
for example, in gse <dig> dataset, our pathway biomarkers got an auc score of  <dig>  compared with  <dig>  by pac biomarkers,  <dig>  by bmi biomarkers and  <dig>  by gene biomarkers.
figure  <dig> shows the results obtained with biomarkers identified by our method compared with the other three methods.
furthermore, we also compared the four methods with respect to accuracy, sensitivity and specificity.
for the dataset of gse <dig>  both pin biomarkers and pac biomarkers achieved an auc score of  <dig>  compared with  <dig>  by bmi biomarkers and  <dig>  by gene biomarkers.
however, pin biomarkers achieved the highest sensitivity and specificity.
the detailed results can be found in additional file 2: table s <dig>  the good performance of our method on both training dataset and the four independent test dataset demonstrates that our identified dysregulated pathways can serve as robust biomarkers.
dysregulated pathways provide insights into pathogenesis of cancer
we further investigated the five identified dysregulated pathways in pancreatic cancer .
from the pathway list, we can find that some identified dysregulated pathways involve hallmark cancer genes, such as p <dig>  nf-κb, pi3k, etc.
figure  <dig> shows the interactions among the five identified dysregulated pathways in pin, including p <dig> signaling pathway, jnk mapk pathway, p <dig> mapk pathway, salmonella pathway, and cdc42rac pathway, where the last four pathways connect with each other.
p <dig> is a well-known tumour suppressor gene, which is involved in various biological processes, including cell cycle, apoptosis and senescence, etc.
<cit> .
mutations that deactivate p <dig> were found in most tumour types, and p <dig> plays an important regulation role in tumour progression.
interestingly, p <dig> signaling pathway was identified as the top dysregulated pathway by our method.
the jnk mapk pathway interacts with p <dig> signaling pathway.
jun n-terminal kinase  is one of mitogen-activated protein kinase  members and also a stress-activated protein kinase.
both p <dig> and jnk are two important apoptosis-regulatory factors frequently deregulated in cancer cells.
they also participate in the modulation of autophagy and can be regulated by tnf alpha , which is a soluble cytokine mediator of immune responses and involved in various biological functions.
jnk and erk mediate tnf alpha-induced p <dig> activation in apoptosis and autophagic activity.
another identified desregulated pathway p <dig> mapk pathway is also involved in this process, where p <dig> is one member of the mapk superfamily.
jnk and p <dig> mapk pathways that are activated by stress and inflammatory signals have crosstalk, thereby working together to affect proliferation, differentiation, survival, and migration.
the p <dig> mapk pathway can negatively regulate jnk activity in several contexts  <cit> .
tnf alpha regulates the jnk and p <dig> mapks in apoptotic and autophagic process in which erk/jnk plays a promoting role while p <dig> plays an inhibiting one  <cit> .
jnk activation can also be negatively regulated by nf-κb which is widely involved in oncogenesis, cell proliferation and apoptosis, and evasion of immune responses  <cit> .
inhibition of nf-κb activation and sustained jnk activation promote the tnf alpha mediated cell apoptotic and suppress the tumour progression  <cit> .
the salmonella pathway and cdc42rac pathway are both related to cell invasion and migration.
cdc <dig> gene is the common differentially expressed gene in four dysregulated pathways indicating its key role in pancreatic tumour.
the cdc42rac pathway regulates cell migration through p <dig> that is a subunit of pi3ks .
p <dig> activates cdc <dig> which affects the formation of new actin fibers and interacts with wiskott–aldrich syndrome protein  to stimulate migration  <cit> .
on the other hand, activated p <dig> can bind to p <dig>  another subunit of pi3k, which can activate akt through pip <dig> that serves as a second messenger.
akt plays a main role in cell survival, proliferation, and growth  <cit> .
the mutation of p <dig> and activation of akt have been found in some primary tumours, including the pancreatic tumour  <cit> .
furthermore, we applied noa  web tools  <cit>  to identify enriched go function for genes in our identified dysregulated pathways.
the top  <dig> enriched go biological processes for each pathway biomarker in pancreatic tumour dataset were listed in table  <dig>  from the analysis, we found that those enriched processes, such as regulation of cell cycle, apoptosis and regulation of cellular component biogenesis, are most important biological processes in tumour progression, thereby implying the effectiveness of our proposed method.
the identified enriched go terms on the other three cancer datasets were listed in additional file 3: table s <dig>
discussion
identifying biomarkers in complex diseases can help diagnose disease and design more effective drugs.
the accumulation of “omics” data, especially gene expression data, makes it possible to detect biomarkers in a more efficient way  <cit> .
however, it is a challenging task to identify robust biomarkers from about  <dig>  genes considering that complex diseases are usually caused from mutations of multiple correlated genes or failure of certain subsystems rather than individual genes.
traditional methods detecting differentially expressed genes as biomarkers failed to work in some cases due to the independent assumption among genes, whereas complex diseases generally affect a set of functionally related genes.
in this paper, we proposed a novel method to identify dysregulated pathways in cancer.
unlike the existing methods, our method considers the functional dependency between pathways by constructing a pathway interaction network.
benchmarking our method on several different cancer datasets demonstrates the effectiveness of the proposed method.
the results on independent test datasets imply the robustness of our identified pathway biomarkers.
further analyses indicate that the dysregulated pathways that we identified are indeed involved in tumour processes, and some of these dysregulated pathways may serve as drug targets in the near future  <cit> .
therefore, the functional relationship between pathways can not only provide insights into disease mechanisms but also provide alternative ways to develop more efficient drugs.
CONCLUSIONS
in this work, we present a novel approach to identify dysregulated pathways in cancer based on a derived pathway interaction network that describes the functional dependency between pathways.
the promising results obtained by our method indicate that the dysregulated pathways indeed have crosstalk with each other.
the comparison between our method and other state of the art methods on multiple cancer datasets demonstrates that our identified dysregulated pathways can serve as robust biomarkers.
we believe that our proposed method can help to predict new biomarkers and even drug targets in a more accurate and robust way.
authors' contributions
xmz conceived the idea and designed the experiments.
kql implemented the algorithm.
kql, xmz, lnc, jkh, and zpl wrote the manuscript.
all authors read and approved the final manuscript.
supplementary material
additional file 1
table s <dig> classification results on four cancer datasets based on the identified dysregulated pathways.
the classification results on four distinct cancer  datasets by pathway biomarkers, compared with pac biomarkers, bmi biomarkers and gene biomarkers.
click here for file
additional file 2
table s <dig> the results of our identified dysregulated pathways on lung cancer test dataset.
the results of our identified dysregulated pathways on lung cancer test dataset, compared with pac biomarkers, bmi biomarkers and gene biomarkers.
click here for file
additional file 3
table s <dig> the list of identified enriched go term in dysregulated pathway biomarkers.
the list of top  <dig> enriched go biological processes of pathway biomarkers in lung cancer  dataset, prostate tumour  and breast tumour  dataset.
click here for file
acknowledgements
this work was partly supported by nsfc , cai yuanpei program supported by csc , shanghai rising-star program , shanghai pujiang program, chief scientist program of sibs of cas , knowledge innovation program of sibs of cas , radapop and ligero projects .

 cancer is a type of complex diseases, which generally involves multiple gene mutations and pathway dysregulations. identifying biomarkers for cancer can help to understand and diagnose diseases, which in turn helps to design drugs with effective therapy. however, it is a challenging task to detect reliable biomarkers in cancers. recently, the accumulation of large amount of “omics” data in public databases provides an opportunity for detecting biomarkers, among which the gene expression data are widely used. accordingly, much effort has been made to identify causal disease genes based on these data. for example, many computational methods have been developed to detect differentially expressed genes between normal and disease samples, and these genes are supposed to be related to diseases and can be used as biomarkers. unfortunately, many of the differentially expressed genes detected in one dataset are later found not to work effectively in another dataset for the same disease, especially for complex diseases. this phenomenon may arise due to the independency assumption among disease related genes when detecting differentially expressed genes, whereas complex diseases are generally caused by the dysregulation of functional modules that consist of a set of genes. due to the poor performance of biomarkers as differentially expressed genes, some approaches have been proposed to identify possible pathogenic pathways, which improves the robustness and accuracy when these pathways are used as biomarkers compared with above mentioned gene based methods. for example, lee et al. proposed to use a subset of genes belonging to one pathway as biomarkers to accurately distinguish diseases from controls. liu et al. used pathways to compare different regions of alzheimer's disease brains and found dysfunctional pathways that cooperate in different brain regions. despite the success of these methods on some datasets, the majority of them do not consider the functional dependency between pathways. generally, different pathways have crosstalk with each other, and the deregulation of one pathway may affect the activities of many related pathways. therefore, it is possible to detect more reliable pathway biomarkers by taking into account the functional dependency or interaction between pathways. in this paper, we propose a novel method to identify dysregulated pathways by considering pathway interactions. the identified dysregulated pathways can be used as candidate biomarkers to diagnose cancer. specifically, a new approach is proposed to construct a pathway interaction network, which describes the functional dependency between pathways. subsequently, the dysregulated pathways in cancer are identified as the best features to discriminate cancers from controls in a machine learning framework. benchmarking our method on several distinct cancer datasets shows that our method outperforms previous state of the art methods. furthermore, functional analysis and independent experimental evidence demonstrate that our identified dysregulated pathways are biologically reasonable, indicating the practical efficiency of the proposed method. methods datasets gene expression data the gene expression datasets were obtained from the ncbi gene expression omnibus. we chose four different types of cancer datasets that have balanced number of disease and control samples in each dataset. table lists the gene expression datasets that were used in this work, including lung cancer, prostate tumour, breast cancer, and pancreatic tumour. for each gene expression dataset, the annotations for probes were obtained from geo and each probe was mapped to a gene, where the probes were discarded if they do not match any gene. the expression value averaged over probes was used as the gene expression value if the gene has multiple probes. subsequently, the expression values of all genes in each dataset were standardized as follows zij=gij−meanstd where gij represents the expression value of gene i in sample j, and mean and std respectively represents mean and standard deviation of the expression vector for gene i across all samples. cellular pathways and human protein-protein interactions the predefined biological pathways were obtained from the molecular signatures database, which is a large collection of annotated functional gene sets. we chose the canonical pathways in the curated gene sets that contain pathways, including the metabolic and signaling pathways collected from biocarta, kegg, and reactome. the human protein-protein interactions were obtained from the human protein reference database, which contains manually curated protein-protein interactions. the ppi data set contains protein interactions among unique human proteins. pathway activity and pathway interaction network pathway activity all the genes were mapped to pathways extracted from msigdb and only those genes that can be mapped to pathways were kept for further analysis hereinafter. after the genes were mapped to pathways, we defined an activity score for each pathway as the summary of the expression values of all genes belonging to this pathway. in particular, we used principal component analysis method to get the summary of all gene expressions of each pathway. the pca technique can effectively characterize the internal structure of high-dimension dataset by preserving the variance in the data while transforming the data into low-dimension space. in brief, the activity score pkj of pathway k in sample j was defined as follows. pkj=w1jkz1jk+w2jkz2jk⋯+wijkzijk where zijk represents the standardized expression value of gene i from pathway k in sample j, and wijk denotes weight for zijk. in other words, the activity of each pathway can be regarded as the linear combination of the expressions of all genes in the pathway, and each pathway can be regarded as a meta-gene. in particular, the first principal component from pca was used as the activity score for the corresponding pathway here. therefore, the pathways that have different activities in diseases between controls are possibly related to diseases. pathway interaction network a pathway interaction network was constructed with each node representing a pathway, where one edge was laid between two pathways if they share at least one gene or there are interactions between genes from the two pathways based on ppis. due to the condition-specificity of gene expression and pathway activity, for a given gene expression dataset, we further required that at least one of the common genes between two pathways is differentially expressed between diseases and controls, or the two genes that code a pair of interacting proteins used to lay an edge between two pathways are highly co-expressed. otherwise, the edge between two pathways will be removed. therefore, a pathway interaction network was constructed for each dataset. the number of pathways and corresponding interactions in each pin built for each dataset were shown in table identifying dysregulated pathways from pathway interaction network after defining the activity score for each pathway, we formulated the identification of dysregulated pathways as a feature selection problem in a machine learning framework, where the minimum set of pathways that can best discriminate diseases from controls were considered to be more possibly dysregulated pathways. it is reasonable and biologically interpretable to consider dysregulated pathways as discriminative features. in detail, a single pathway that can best discriminate between diseases and controls was firstly identified as the first pathway biomarker, and the second pathway that can be combined with the first pathway to get better classification results was identified from those pathways that interact with the first pathway in pin. this procedure was repeated to add new pathways to selected pathway biomarkers until no more pathways can be added to improve classification accuracy, and the final selected pathway biomarkers were retained as potential dysregulated pathways in diseases. in feature selection, we used support vector machines, which is a widely used kernel based method especially useful for small number of samples with high dimensional variables. in this work, the libsvm toolbox was used with radial basis functional kernel. the performance of the classifier was evaluated with five-fold cross validation, and auc score was adopted as classification performance index. in the five-fold cross validation, all samples were randomly split into five equal-size subsets without overlap, four of which were used as training set while the rest one was used to evaluate the classification performance. to get robust results, we repeated five-fold cross-validation for times and the average was used as the final result in each dataset.  identification of dysregulated pathways in cancer to evaluate our method, we applied it to identify dysregulated pathways for the four cancer datasets listed in table moreover, we used these pathways to discriminate diseases from controls and compared our results with two classical differentially expressed gene detection methods, including the student’s t-test and biomarker identifier method. in the bmi method, the differentially expressed genes were ranked by logistic regression analysis, and this method was shown to outperform other methods. the genes selected by student’s t-test and bmi were respectively denoted as gene biomarkers and bmi biomarkers hereinafter. for comparison with student’s t-test and bmi, we picked the same number of top ranked genes by these two methods as that of our selected pathways. figure shows the results obtained by gene biomarkers and bmi biomarkers compared with our method. the dysregulated pathways identified by our method in four cancer datasets were respectively listed in tables  we can clearly see from the results that our method outperforms the other two methods on all four different cancer datasets, indicating the effectiveness and efficiency of our proposed method. for example, for lung cancer dataset, our method performed very well with an auc score of compared against gene biomarker with an auc score of and bmi biomarker with an auc score of. except for the auc score, we also compared the four methods with respect to accuracy, sensitivity and specificity. the promising results obtained by the proposed method also demonstrate that our identified pathway biomarkers are potential dysregulated pathways in cancer. moreover, we also compared our method with one state of the art dysregulation pathway identification method, i.e., pac method, proposed by lee et al.. in the pac method, the pathway activity was defined as a combined score of a subset of genes, called the condition-responsive genes, that yields the best discriminative score. the pathways with different discriminative power were subsequently ranked based on t-test. we performed the pac method on above four cancer datasets. for a fair comparison, we used the same svm toolbox and the same number of pathways identified by our method. the results of the pac method were also shown in figure. as shown in figure our proposed method achieved a higher auc score than the pac method on all four datasets. these results indicate that our proposed approach helps to improve the discriminative power by taking into account the functional dependency between pathways. furthermore, we compared the genes involved in our identified dysregulated pathways with those top ranked differentially expressed genes. table lists the numbers of genes involved in both our identified dysregulated pathways and those top ranked differentially expressed genes. it is found that only a small fraction of the genes in our identified dysregulated pathways overlaps with top ranked differentially expressed genes. this phenomenon implies that a pathway as an entity can better diagnose complex diseases rather than individual genes even though the genes in the pathway are not differentially expressed significantly. dysregulated pathways are robust as biomarkers to further test our method, we applied the identified dysregulated pathways from above lung cancer dataset to other four independent hold-out datasets of lung cancer that are from two different affymetrix platforms, i.e., gpl and gpl. note that all of these test datasets list in table are not used in above section, thereby evaluating our proposed method in an objective way. similarly, the gene or pathway biomarkers selected from gse dataset by other methods were also applied to the four lung cancer test datasets. the same numbers of pathways or genes as that of our selected pathways were chosen for a fair comparison. the pathway biomarkers identified by our method achieved higher or comparable auc scores compared with other methods on all four datasets. for example, in gse dataset, our pathway biomarkers got an auc score of compared with by pac biomarkers, by bmi biomarkers and by gene biomarkers. figure shows the results obtained with biomarkers identified by our method compared with the other three methods. furthermore, we also compared the four methods with respect to accuracy, sensitivity and specificity. for the dataset of gse both pin biomarkers and pac biomarkers achieved an auc score of compared with by bmi biomarkers and by gene biomarkers. however, pin biomarkers achieved the highest sensitivity and specificity. the detailed results can be found in additional file 2: table s the good performance of our method on both training dataset and the four independent test dataset demonstrates that our identified dysregulated pathways can serve as robust biomarkers. dysregulated pathways provide insights into pathogenesis of cancer we further investigated the five identified dysregulated pathways in pancreatic cancer. from the pathway list, we can find that some identified dysregulated pathways involve hallmark cancer genes, such as p nf-κb, pi3k, etc. figure shows the interactions among the five identified dysregulated pathways in pin, including p signaling pathway, jnk mapk pathway, p mapk pathway, salmonella pathway, and cdc42rac pathway, where the last four pathways connect with each other. p is a well-known tumour suppressor gene, which is involved in various biological processes, including cell cycle, apoptosis and senescence, etc.. mutations that deactivate p were found in most tumour types, and p plays an important regulation role in tumour progression. interestingly, p signaling pathway was identified as the top dysregulated pathway by our method. the jnk mapk pathway interacts with p signaling pathway. jun n-terminal kinase is one of mitogen-activated protein kinase members and also a stress-activated protein kinase. both p and jnk are two important apoptosis-regulatory factors frequently deregulated in cancer cells. they also participate in the modulation of autophagy and can be regulated by tnf alpha, which is a soluble cytokine mediator of immune responses and involved in various biological functions. jnk and erk mediate tnf alpha-induced p activation in apoptosis and autophagic activity. another identified desregulated pathway p mapk pathway is also involved in this process, where p is one member of the mapk superfamily. jnk and p mapk pathways that are activated by stress and inflammatory signals have crosstalk, thereby working together to affect proliferation, differentiation, survival, and migration. the p mapk pathway can negatively regulate jnk activity in several contexts. tnf alpha regulates the jnk and p mapks in apoptotic and autophagic process in which erk/jnk plays a promoting role while p plays an inhibiting one. jnk activation can also be negatively regulated by nf-κb which is widely involved in oncogenesis, cell proliferation and apoptosis, and evasion of immune responses. inhibition of nf-κb activation and sustained jnk activation promote the tnf alpha mediated cell apoptotic and suppress the tumour progression. the salmonella pathway and cdc42rac pathway are both related to cell invasion and migration. cdc gene is the common differentially expressed gene in four dysregulated pathways indicating its key role in pancreatic tumour. the cdc42rac pathway regulates cell migration through p that is a subunit of pi3ks. p activates cdc which affects the formation of new actin fibers and interacts with wiskott–aldrich syndrome protein to stimulate migration. on the other hand, activated p can bind to p another subunit of pi3k, which can activate akt through pip that serves as a second messenger. akt plays a main role in cell survival, proliferation, and growth. the mutation of p and activation of akt have been found in some primary tumours, including the pancreatic tumour. furthermore, we applied noa web tools to identify enriched go function for genes in our identified dysregulated pathways. the top enriched go biological processes for each pathway biomarker in pancreatic tumour dataset were listed in table from the analysis, we found that those enriched processes, such as regulation of cell cycle, apoptosis and regulation of cellular component biogenesis, are most important biological processes in tumour progression, thereby implying the effectiveness of our proposed method. the identified enriched go terms on the other three cancer datasets were listed in additional file 3: table s discussion identifying biomarkers in complex diseases can help diagnose disease and design more effective drugs. the accumulation of “omics” data, especially gene expression data, makes it possible to detect biomarkers in a more efficient way. however, it is a challenging task to identify robust biomarkers from about genes considering that complex diseases are usually caused from mutations of multiple correlated genes or failure of certain subsystems rather than individual genes. traditional methods detecting differentially expressed genes as biomarkers failed to work in some cases due to the independent assumption among genes, whereas complex diseases generally affect a set of functionally related genes. in this paper, we proposed a novel method to identify dysregulated pathways in cancer. unlike the existing methods, our method considers the functional dependency between pathways by constructing a pathway interaction network. benchmarking our method on several different cancer datasets demonstrates the effectiveness of the proposed method. the results on independent test datasets imply the robustness of our identified pathway biomarkers. further analyses indicate that the dysregulated pathways that we identified are indeed involved in tumour processes, and some of these dysregulated pathways may serve as drug targets in the near future. therefore, the functional relationship between pathways can not only provide insights into disease mechanisms but also provide alternative ways to develop more efficient drugs.  in this work, we present a novel approach to identify dysregulated pathways in cancer based on a derived pathway interaction network that describes the functional dependency between pathways. the promising results obtained by our method indicate that the dysregulated pathways indeed have crosstalk with each other. the comparison between our method and other state of the art methods on multiple cancer datasets demonstrates that our identified dysregulated pathways can serve as robust biomarkers. we believe that our proposed method can help to predict new biomarkers and even drug targets in a more accurate and robust way. authors' contributions xmz conceived the idea and designed the experiments. kql implemented the algorithm. kql, xmz, lnc, jkh, and zpl wrote the manuscript. all authors read and approved the final manuscript. supplementary material additional file 1 table s classification results on four cancer datasets based on the identified dysregulated pathways. the classification results on four distinct cancer datasets by pathway biomarkers, compared with pac biomarkers, bmi biomarkers and gene biomarkers. click here for file additional file 2 table s the results of our identified dysregulated pathways on lung cancer test dataset. the results of our identified dysregulated pathways on lung cancer test dataset, compared with pac biomarkers, bmi biomarkers and gene biomarkers. click here for file additional file 3 table s the list of identified enriched go term in dysregulated pathway biomarkers. the list of top enriched go biological processes of pathway biomarkers in lung cancer dataset, prostate tumour and breast tumour dataset. click here for file acknowledgements this work was partly supported by nsfc, cai yuanpei program supported by csc, shanghai rising-star program, shanghai pujiang program, chief scientist program of sibs of cas, knowledge innovation program of sibs of cas, radapop and ligero projects.
in this work, by utilizing pathway interaction networks and gene expression data, we propose a novel approach that effectively identifies dysregulated pathways, which can not only be used as biomarkers to diagnose cancers but also serve as potential drug targets in the future. firstly, we present a new method to construct pathway interaction network based on gene expression, protein-protein interactions and cellular pathways. secondly, the identification of dysregulated pathways in cancer is treated as a feature selection problem, which is biologically reasonable and easy to interpret. cancers, a group of multifactorial complex diseases, are generally caused by mutation of multiple genes or dysregulation of pathways. the benchmarking results on several distinct cancer datasets demonstrate that our method can obtain more reliable and accurate results compared with existing state of the art methods. traditional computational methods that detect genes differentially expressed between cancer and normal samples fail to work due to small sample size and independent assumption among genes. in this paper, we propose a novel approach to identify dysregulated pathways in cancer based on a pathway interaction network. further functional analysis and independent literature evidence also confirm that our identified potential pathogenic pathways are biologically reasonable, indicating the effectiveness of our method. thirdly, the dysregulated pathways are identified as subnetworks from the pathway interaction networks, where the subnetworks characterize very well the functional dependency or crosstalk between pathways.
 cancers, a group of multifactorial complex diseases, are generally caused by mutation of multiple genes or dysregulation of pathways. identifying biomarkers that can characterize cancers would help to understand and diagnose cancers. traditional computational methods that detect genes differentially expressed between cancer and normal samples fail to work due to small sample size and independent assumption among genes. on the other hand, genes work in concert to perform their functions. therefore, it is expected that dysregulated pathways will serve as better biomarkers compared with single genes.  in this paper, we propose a novel approach to identify dysregulated pathways in cancer based on a pathway interaction network. our contribution is three-fold. firstly, we present a new method to construct pathway interaction network based on gene expression, protein-protein interactions and cellular pathways. secondly, the identification of dysregulated pathways in cancer is treated as a feature selection problem, which is biologically reasonable and easy to interpret. thirdly, the dysregulated pathways are identified as subnetworks from the pathway interaction networks, where the subnetworks characterize very well the functional dependency or crosstalk between pathways. the benchmarking results on several distinct cancer datasets demonstrate that our method can obtain more reliable and accurate results compared with existing state of the art methods. further functional analysis and independent literature evidence also confirm that our identified potential pathogenic pathways are biologically reasonable, indicating the effectiveness of our method.  dysregulated pathways can serve as better biomarkers compared with single genes. in this work, by utilizing pathway interaction networks and gene expression data, we propose a novel approach that effectively identifies dysregulated pathways, which can not only be used as biomarkers to diagnose cancers but also serve as potential drug targets in the future. 